key: cord-0916301-6tkr4n70
authors: Githaka, John Maringa
title: Molnupiravir Does Not Induce Mutagenesis in Host Lung Cells during SARS-CoV-2 Treatment
date: 2022-03-23
journal: Bioinform Biol Insights
DOI: 10.1177/11779322221085077
sha: 2f7cdec56f4672b9a1f41fb95e36025e3dde4b2c
doc_id: 916301
cord_uid: 6tkr4n70

As SARS-CoV-2 continues to evolve and spread with the emergence of new variants, interest in small molecules with broad-spectrum antiviral activity has grown. One such molecule, Molnupiravir (MOV; other names: MK-4482, EIDD-2801), a ribonucleoside analogue, has emerged as an effective SARS-CoV-2 treatment by inducing catastrophic viral mutagenesis during replication. However, there are growing concerns as MOV’s potential to induce host DNA mutagenesis remains an open question. Analysis of RNA-seq data from SARS-CoV-2–infected MOV-treated golden hamster lung biopsies confirmed MOV’s efficiency in stopping SARS-CoV-2 replication. Importantly, MOV treatment did not increase mutations in the host lung cells. This finding calls for additional mutation calls on host biopsies from more proliferative tissues to fully explore MOV’s hypothesized mutagenic risk.

Despite the efficiency of vaccines in combating COVID-19, the emergence and spread of SARS-CoV-2 variants of concern increases the threat of potential escape from "natural or vaccine-induced immunity." 1 Broad-spectrum preventive or treatment drug options offer an alternative in keeping up with SARS-CoV-2 evolution. 2 Molnupiravir (MOV) is an oral antiviral medication that inhibits SARS-CoV-2 replication through viral RNA mutation buildup. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Unlike other ribonucleoside analogue antiviral agents, key to MOV's efficiency in inducing catastrophic viral mutagenesis is its ability to evade SARS-CoV-2 exonuclease proofreading activity. 8 MOV has shown promising phase 3 MOVe-OUT clinical trial results where early treatment "reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19." 12, 13 Importantly, MOV was effective against all three SARS-CoV-2 variants of concern (delta, gamma, and mu) which were tested. 12, 13 Despite the encouraging results, there are growing concerns for potential host cell's mutagenesis since MOV's active metabolite, β-D-N 4 -hydroxycytidine (NHC), can be metabolized to 2′-deoxyribonucleotide and theoretically incorporated into the host genome. A recent in vitro hypoxanthine phosphoribosyltransferase (HPRT) mutation assay in Chinese hamster ovary (CHO-K1) cells suggested potential NHC-induced mutations. 5 Indeed, their RNA sequencing of HPRT gene showed missense substitution and frame shifts mutations. 5 Given the lack of in vitro or in vivo whole genome/exome sequences for host cells which have been exposed to MOV, potential global host DNA mutagenesis remains an open question. Here, publicly available RNA-seq data were used as a surrogate for probing host DNA mutations as this would show up in the resultant mRNA transcripts. Results confirm MOV's efficiency in SARS-CoV-2 elimination. Importantly, there was no increase in mutational load in host cells lung biopsy. I also offer a perspective on additional tests that would help in assuring the scientific community and general public of MOV's safety.

Lung biopsy samples (GSE168095; see Table 1 ) paired-end RNA-seq reads (fastq format) were downloaded from NCBI's Sequence Read Archive (SRA). 2 They included uninfected (n = 2), infected vehicle-treated (n = 4), and infected MOV (MK-4482, EIDD-2801) treated (n = 4).

Reads were preprocessed with fastp (version 0.23.1) 14 and subsequently split simultaneously into reads mapping golden hamster reference genome (MesAur1.0) and SARS-CoV-2 reference genome (NC_045512.2) using BBsplit function in BBmap (version 38.86). 15 This approach has been successfully used on SARS-CoV-2 before. 4 The splice aware aligner, STAR (version 2.7.9a), 16 was used to align the dichotomized reads to their respective genome. Mutation calls was done on the resultant aligned MesAur1.0 ".bam" files using Strelka2 (version 2.9.2) 17 which was recently shown to be optimal for variant calling even in low-read-depth single cells RNA-seq data. 18 The -rna flag option was used to activate experimental settings for RNA-seq data variant calling. Only confident calls (mutations with a "PASS" filter flag) were considered for downstream analysis. BCFtools stats 19 was used to extract out the statistics of the mutations called. SnpEff 20 was used to annotate the mutations called and extract out missense and frameshift variants. Annotated VCF files are deposited here https://github. com/maringa780/Molnupiravir-VCF. 

To date, the study by Bakowski et al 2 is the only one with publicly available RNA-seq data on MOV-exposed host biopsy (GSE168095). Briefly, the authors orally administered MOV or vehicle to golden hamsters, 4 hours prior to intranasal infection with SARS-CoV-2 ( Figure 1A ). They also included untreated/ uninfected control animals (see Table1) . Lung biopsies were collected 5 days post infection and analyzed using RNA-seq platform. In the current analysis, RNA-seq reads were downloaded, processed for quality control, and simultaneously mapped to golden hamster (MesAur1.0) and SARS-CoV-2 (NC_045512.2) genome (see section "Methods"). 98.5 ± 1.2% and 1.5 ± 1.2% (mean ± SEM) of reads mapped hamster and SARS-CoV-2 genomes, respectively, in untreated SARS-CoV-2-infected animals, a range observed earlier. 4 In contrast, 99.999979 ± 0.0000079% and 0.000021 ± 0.0000079% of reads mapped hamster and SARS-CoV-2 genomes, respectively, in MOV-treated SARS-CoV-2-infected animals, indicative of MOV's ability to diminish SARS-CoV-2 RNA replication. In line with this, SARS-CoV-2-infected MOV-treated samples were indistinguishable from uninfected samples in unsupervised hierarchical clustering ( Figure 1B) . In contrast, infected vehicletreated samples had detectable high levels of SARS-CoV-2 gene count ( Figure 1B) . This is consistent with previous studies showing MOV's ability to block SARS-CoV-2 replication. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] No signs of MOV-induced mutagenesis in host lung cells Next, mutation calls for reads mapping to golden hamster genome was done using appropriate parameters for RNA-seq platform data. Filtering was done to only compare high confident mutational calls (see section "Methods"). There was no significant difference in absolute numbers and percentile distribution of both substitution and indel mutations ( Figure 1C ). In addition, the substitutions and indels did not significantly change the number of gene missense and frameshift variants, respectively ( Figure 1C ). Taken together, there was no differential mutation enrichment under MOV treatment.

While MOV's clinical trials have been promising, it is imperative that all possible risks are fully assessed to enable objective risk-benefit analysis decisions. The mutation analysis described here shows no signs of increased mutations in MOV-treated host lung biopsies. However, cell turnover/proliferation, a key requirement for mutagenesis induction, could be a confounding factor since it is quite low in the lungs. 21 Potential genotoxicity of MOV has been addressed in part by Merck (Pharmaceutical company developing MOV) through in vivo Pig-a mutation assay, and Big Blue (cII Locus) transgenic assay in rats. 10 In both assays, there was no difference in mutation rates observed between untreated and MOV-treated animals. 10 This is in line with the current result showing lack of additional mutations in the host lung cells. While details of animal tissue used for the Big Blue assay have not been published, Pig-a assay uses blood samples, 22 serving as an excellent sample source since blood cells have some of the highest cell turnover. 21 It is worth noting that in vivo Pig-a assay had 82.4% sensitivity in a recent analysis of in vivo genotoxicity assays in detecting human carcinogens. 23 Combining it with in vivo micronucleus assay was shown to improve the sensitivity to 94.1%. 23 Following this recommendation, Merck did "in vitro micronucleus (with and without metabolic activation) and in vivo rat micronucleus assays," with Githaka 3 both assays showing no MOV-induced chromosomal damage. 10 Nevertheless, the conclusion that "MOV is not considered to pose an increased risk of genotoxicity in clinical use" 10 has been questioned by other researchers owing to lack of details on protocol used and assay sensitivity. 24, 25 While NHC (MOV's active metabolite) showed positive mutagenesis in Zhou et al 5 in vitro HPRT genotoxicity assay, the cells were cultured in the presence of NHC for 32 days in contrast to the typical 5 days of MOV treatment in animal studies 2 and clinical trials. 12, 13, 26 Interestingly, cells exposed to 1 minute of UV light showed higher (~1.3-fold to ~4.4-fold) inferred mutation effect compared to NHC's highest effect in the HPRT genotoxicity assay. 5 Given the contradicting results between Merck and Zhou et al read-outs of mutagenesis assays, 5,10 whole genome/exome deep sequencing of highly proliferative host cells or tissues under MOV exposure would provide an unbiased broader perspective on global mutational differences if any. The necessity for this cannot be overstated given the potential implications of genotoxicity in initiating cancer or birth defects.

With mounting concerns on MOV's safety being expressed within the scientific community and in mainstream media, 27 more publicly available scientific data on MOV's short-term or long-term genotoxic effect are needed to address legitimate questions raised. No matter what the data will show, this approach will strengthen public trust in the scientific community and the process of testing all available evidence to ensure public safety. In the meantime, MOV's use should be restricted to COVID-19 patients with risk factor(s) for developing severe disease as its benefits would outweigh the hypothesized mutagenic risk.

J.M.G. conceived the study, conducted dataset searches, mutation analysis and wrote the paper.

Annotated mutation VCF files are deposited here: https:// github.com/maringa780/Molnupiravir-VCF.

John Maringa Githaka https://orcid.org/0000-0003-1974-0415. 

Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines

Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. Nat Commun

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801

β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis

Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template

A novel model of molnupiravir against SARS-CoV-2 replication: accumulated RNA mutations to induce error catastrophe

RdRp inhibitors and COVID-19: is molnupiravir a good option? Biomed Pharmacother

Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19

Decoding molnupiravir-induced mutagenesis in SARS-CoV-2

Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients

Molnupiravir-a step toward orally bioavailable therapies for Covid-19

fastp: an ultra-fast all-in-one FASTQ preprocessor

BBMap: a fast, accurate, splice-aware aligner

STAR: ultrafast universal RNA-seq aligner

Strelka2: fast and accurate calling of germline and somatic variants

Systematic comparative analysis of single-nucleotide variant detection methods from single-cell RNA sequencing data

Twelve years of SAMtools and BCFtools

A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3

The distribution of cellular turnover in the human body

The pig-a gene mutation assay in mice and human cells: a review

A critical appraisal of the sensitivity of in vivo genotoxicity assays in detecting human carcinogens

Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis-the special case of molnupiravir

A phase 2a clinical trial of Molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

A prominent virologist warns COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm-Science-AAAS